Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
1992-2-4
|
| pubmed:abstractText |
Bemitil, administered orally in a dose of 0.25-0.5 g a day for 5-7 days at the acute period of the relapse of erysipelas as an immunostimulant, enhanced the effectiveness of the basic therapy including antibiotics, anti-inflammatory and antiallergic drugs, vitamins, plasma-substituting fluids and saline solutions, as well as ultraviolet irradiation of the focus of lesion. Bemitil therapy was associated with an increase in the number of T-lymphocytes, normalization of the balance between the peripheral lymphocyte preparations, an increase of blood serum levels of IgA and IgM.
|
| pubmed:language |
rus
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0372-9311
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
56-8
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:1759524-Adjuvants, Immunologic,
pubmed-meshheading:1759524-Antibody Formation,
pubmed-meshheading:1759524-Benzimidazoles,
pubmed-meshheading:1759524-Combined Modality Therapy,
pubmed-meshheading:1759524-Drug Evaluation,
pubmed-meshheading:1759524-Erysipelas,
pubmed-meshheading:1759524-Humans,
pubmed-meshheading:1759524-Immunity, Cellular,
pubmed-meshheading:1759524-Length of Stay,
pubmed-meshheading:1759524-Recurrence,
pubmed-meshheading:1759524-Time Factors
|
| pubmed:year |
1991
|
| pubmed:articleTitle |
[The dynamics of the immunological indices during the treatment of recurrent erysipelas with the new immunostimulant bemitil].
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
English Abstract
|